

J

volume 30 | number 2 | pages 101–166 | April 2010

Autonomic & Autacoid Pharmacology



 **WILEY-
BLACKWELL**

ISSN 1474 8665 (Print)
ISSN 1474 8673 (Online)

PLENARY LECTURES

Ace of polybacterial immunostimulants in medical practice

B. Petrunov

National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria

Medical practice faces serious problems due to the constantly increasing bacterial poly-resistance to antibiotics, and the side effects of the latter, often including allergic and immunosuppressive reactions. One way to resolve this problem is the application of immunomodulator that increase resistance to bacterial and viral infections by stimulating non-specific immunity mechanisms. In the course of more than 20 years a number of oral immunomodulator have been developed and investigated in the NCIPD, Sofia: Respivax, Urostim and Dentavax are widely and successfully applied in clinical practice for immunotherapy and immunomodulation. Data about the effects of polybacterial immunomodulator demonstrate a pronounced stimulation of phagocytosis, synthesis of secretory IgA, surfactant, interferon and a number of Th1 types of cytokines. Numerous investigations, including double-blind studies, have proved their efficacy in the prevention and treatment of non-specific respiratory, uro-genital, and periodontal infections as well as in the complex therapy of AIDS. Based on this, polybacterial immunostimulators seem a very promising tool for immunotherapy and immunoprevention, allowing the modulation of immune responses in a most beneficial way.

Key words Polybacterial immunostimulation, immune system, non-specific immunotherapy and immunoprophylaxis, immunostimulation

References

1. DOBREV P., NIKOLOVA P., STANKOVA S. (1989). Prevention of respiratory infections with Bulgarian immunostimulator Respivax, *Pneumology and Phthisiatry.*, 27, 27–31.
2. ILIEV I., RADANOVA V., GEORGIEVA P. (1990). Clinical and immunological results after treatment with Respivax of children with different pulmonary diseases, *Pediatrics*. 29, 55–61.
3. KOJOUHAROVA M., PETRUNOVA S., PANOVA N. (1998). The influence of Respivax on the level of endogenous Alfa-interferon. *Infectology*. 35, 30–32.
4. KOJOUHAROVA M., GACHEVA N., VLADIMIROVA N. (1999). The effect of immunostimulator Respivax on the immunogeneses after Td vaccination. *Infectology.*, 36, 25–27.
5. PETRUNOV B., NENKOV P., CVETANOV I. (1999). Study the effect of the polybacterial immunostimulator Respivax in the course of immunoprophylaxis and immunotherapy non-specific respiratory infections. *JMEI.*, 4, 34–39.
6. STOICHKOV I. *et al.* (1990). Immunomodulators and cancer. Sofia, Medicina and Phiscultura Ed.
7. AHRENS J., Bronhovaxom in clinical practice. (1984). Scientific Proceedings OM Laboratories. Geneva, 29–39.
8. CVETANOV J., PETRUNOV B., NENKOV P., DRAGULEV B. (1989). Immunomorphological changes in the lymphnodes and parenchym organs of mice treated with Respivax. *Problems of Infect. Parasitic Dis.*, 26, 81–89.
9. HO, D. (1994). Long term non-progressors. Proceedings of X Inter. Conference on AIDS, Yokohama, Japan.
10. KASSABOV K., STOICHKOV J. (1990). Inhibitory effect of the oral preparation Respivax on pulmonary metastasis of Lewis lung carcinoma in mice. *C.R. Acad. Bulg. Sci.*, 43, 117–119.
11. JOSSIFOV J., BAKALOVA S., STANKOVA S. *et al.* (1989). Use of Respivax for prophylaxis of bronchopulmonary infections in children. *Pneumology*. 9, 20–23.
12. KISYOVA K., ZLATANOV Z., PENEVA M. *et al.* (1989). Evaluation of immunostimulants used in pulmologic practice. *Inter. Diseases.*, 21, 85–90.
13. KLAUSEN B., EVANS R., RAMAMURTHY N., GOLUB N. *et al.* (1991). Periodontal bone level and gingival proteinase activity in gnotobiotic rats immunized with *Bacteroides gingivalis*. *Oral Microbial. Immunol.*, 6, 193–201.
14. LEVY, J. (1994). Research findings and future prospects in AIDS. Proc. X Inter. Conference on AIDS, Yokohama, Japan.

15. MAESTRONY C., LOSA G. (1984). Polybacterial immunostimulants in respiratory diseases. Scientific Proceedings OM Laboratories, Geneva, 56–65.
16. MARINOVA S., TCHORBADJIJSKA L. *et al.* (2000). Immunostimulating and protective effects of an oral polybacterial immunomodulator in rabbit experimental model. *Int. J. Immunopharmac.*, 22, 843–854.
17. MARKOVA R., MARINOVA S., PETRUNOV B., CVETANOV J. *et al.* (1997). Stimulating effect of an oral polybacterial immunostimulator on the proliferation activity of guinea pig lymphocytes. *Int. J. Immunopharmac.*, 19, 205–214.
18. MORIKAWA K., OSEKO F., MORIKAWA S. (1993). Immunomodulatory effect of Fosfomycin on human B- lymphocyte function. *Antimicrob. Agents Chemother.*, 37, 270–275.
19. PAGE R. (1995). Vaccine development for periodontal diseases. *Mucosal Immunology Update.*, 3, 9–11.
20. PERSSON G., ENGEL L., WHINEY C. *et al.* (1994). *Macaca fascicularis* as a model in which to assess the safety and efficacy of a vaccine for periodontitis. *Oral Microbiol. Immunol.*, 9, 104–111.
21. PETRUNOV B., NENKOV P., MARINOVA S. *et al.* (1993). New per oral immunostimulator for immunotherapy and immunoprophylaxis of non-specific infections in the mouth and parodont. *Infectology.*, XX, 24–31.
22. PETRUNOV B., NENKOV P., WRIGHT D., RAINES B., WILLIAMS I. (1996). Evaluation of polybacterial immunostimulant Factor-R on patients with HIV-infection. *Probl. Inf. Parasit. Dis.*, 23, 25–28.
23. PETRUNOV B., NENKOV P. (2004). The role of immunostimulants in immunotherapy and immunoprophylaxis of newly emerging or intentionally spread / bioterrorism / infectious diseases. In: A. Monov (Ed.). Boiterrorism. Bruxell/NATO, (in press).
24. PETRUNOV B. (2004). Study the effect of the polybacterial immunostimulant Respivax on some non-specific immune mechanisms. *C.R. Acad. Bulg. Sci.*, 57, 37–41.